Core Insights - CloudTop New Horizon (1952.HK) announced strategic cooperation agreements with Haisen Biopharmaceuticals, including a commercialization service agreement and a licensing agreement [1][2] Group 1: Commercialization Service Agreement - CloudTop New Horizon's subsidiary will provide commercialization services for six mature products from Haisen Biopharmaceuticals, including Ceftriaxone, Somatostatin, Urapidil, Azilsartan, Candesartan, and Voglibose [1] - The service fee will range from 20% to 55% of the quarterly net sales of the relevant products, with annual payment caps of 560 million, 616 million, and 677 million yuan for the years 2026 to 2028 [1] Group 2: Licensing Agreement - The licensing agreement grants CloudTop New Horizon exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in Greater China [2] - Lerodalcibep is a third-generation PCSK9 inhibitor aimed at lowering LDL-C levels in patients with high cholesterol, with a significant unmet medical need in China [2] - The product is expected to submit a biopharmaceutical application in Greater China in the first half of 2026, with potential approval and market launch by 2027 [2]

Core Viewpoint - Genting New Year (01952) saw a significant increase of over 4% in its stock price, attributed to the announcement of two strategic cooperation agreements with Haisen Biopharmaceutical Co., Ltd. [1] Group 1: Strategic Cooperation Agreements - Genting New Year’s wholly-owned subsidiary, Genting New Year Pharmaceutical Technology Co., Ltd., signed two strategic cooperation agreements with Haisen Biopharmaceutical [1] - Under the commercialization service agreement, Genting New Year Pharmaceutical Technology will leverage its existing sales and marketing system to provide commercialization services for six mature products from Haisen Biopharmaceutical, focusing on critical care, cardiovascular, and metabolic fields [1] Group 2: Licensing Agreement - The licensing agreement grants Genting New Year Pharmaceutical Technology exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in Greater China, enhancing its late-stage pipeline [1] - Genting New Year Pharmaceutical Technology will make an initial payment of approximately 205 million yuan, with potential development and regulatory milestone payments not exceeding 212 million yuan, and potential sales milestone payments not exceeding 1.977 billion yuan, along with royalties based on net sales [1]